Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P970004/S449

InterStim Therapy System, Verify Evaluation System

Medtronic Neuromodulation · Decision date May 1, 2026

FDA DECISIONP970004/S449

What did the FDA decide?

FDA records P970004/S449 as a supplement to PMA P970004, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated May 1, 2026.

FDA approval order statement

Approval for updates to the software programs on the Medium Rate battery line at Medtronic supplier, Medtronic Energy and Component Center (MECC).
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Gastroenterology, Urology
Decision date
May 1, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P970004/S449
Regulatory pathway
PMA supplement
Product code
EZW
Decision code
OK30
Decision date
May 1, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, electrical, implantable, for incontinence.

Product code
EZW
FDA device class
3

For the original device and its historical approval scope, see PMA P970004. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P970004 · Original PMA

    MEDTRONIC INTERSTIM THERAPY SYSTEM FOR URINARY CONTROL

  2. P970004/S427 · Related supplement

    InterStim Therapy System, Verify Evaluation System

  3. P970004/S428 · Related supplement

    InterStim Therapy System, Verify Evaluation System

  4. P970004/S430 · Related supplement

    InterStim Therapy System; Verify Evaluation System

  5. P970004/S431 · Related supplement

    InterStim Therapy System, Verify Evaluation System

  6. P970004/S432 · Related supplement

    InterStim Therapy System, Verify Evaluation System

  7. P970004/S433 · Related supplement

    InterStim Therapy System; Verify Evaluation System

  8. P970004/S434 · Related supplement

    InterStim Therapy System; Verify Evaluation System

  9. P970004/S421 · Related supplement

    InterStim Therapy System

  10. P970004/S436 · Related supplement

    InterStim Therapy System, Verify Evaluation System

  11. P970004/S435 · Related supplement

    InterStim Therapy System, Verify Evaluation System (SNS Urinary Neurostimulator 97800); (SNS Urinary Neurostimulator I

  12. P970004/S438 · Related supplement

    InterStim Therapy System, Verify Evaluation System

  13. P970004/S426 · Related supplement

    InterStim Therapy System, Verify Evaluation System

  14. P970004/S439 · Related supplement

    InterStim Therapy System, Verify Evaluation System

  15. P970004/S441 · Related supplement

    InterStim Therapy System; Verify Evaluation System

  16. P970004/S442 · Related supplement

    InterStim Therapy System, Verify Evaluation System

  17. P970004/S443 · Related supplement

    InterStim Therapy System, Verify Evaluation System

  18. P970004/S424 · Related supplement

    InterStim TM Therapy System, Verify Evaluation System

  19. P970004/S437 · Related supplement

    InterStim Therapy System, Verify Evaluation System

  20. P970004/S444 · Related supplement

    SNS Urinary Neurostimulator Models 97800, 97810; SNS Urinary Screening Trialing Systems Model 3531

  21. P970004/S440 · Related supplement

    InterStim Therapy System, Verify Evaluation System (SNS Urinary Programming Systems A510, A511, A520, A521)

  22. P970004/S445 · Related supplement

    InterStim Therapy System, Verify Evaluation System

  23. P970004/S446 · Related supplement

    InterStim Therapy System, Verify Evaluation System (SNS Urinary Neurostimulator)

  24. P970004/S447 · Related supplement

    InterStim Therapy System, Verify Evaluation System (SNS Urinary Implantable Neurostimulators 97800, 97810)

  25. P970004/S449 received

    Application receipt date recorded by FDA.

  26. P970004/S449 · FDA decision

    30-Day Notice

  27. P970004/S448 · Related supplement

    InterStim Therapy System, Verify Evaluation System

  28. P970004/S450 · Related supplement

    InterStim Therapy System; Verify Evaluation System (3550-05, 3560031, 3889, 978A1, 978B1)

  29. P970004/S451 · Related supplement

    InterStim Therapy System; Verify Evaluation System; InterStim SNS Urinary Lead Model 978B1

  30. P970004/S452 · Related supplement

    InterStim TM Therapy System; Verify TM Evaluation System (97800)

  31. P970004/S453 · Related supplement

    InterStim Therapy System

  32. P970004/S454 · Related supplement

    InterStim Therapy System, Verify Evaluation System

  33. P970004/S455 · Related supplement

    InterStim Therapy System, Verify Evaluation System

  34. P970004/S456 · Related supplement

    InterStim Therapy System, Verify Evaluation System

  35. P970004/S458 · Related supplement

    InterStim Therapy System Verify Evaluation System

  36. P970004/S457 · Related supplement

    InterStim Therapy System, Verify Evaluation System

  37. P970004/S459 · Related supplement

    InterStim Therapy System, Verify Evaluation System

  38. P970004/S460 · Related supplement

    InterStim Therapy System, Verify Evaluation System (SNS Urinary Neurostimulator 97800), (SNS Urinary Neurostimulator I

Timeline entries are records held by MedtechLedger for P970004. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P970004

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic NeuromodulationPMA approvalSep 29, 1997FDA
Medtronic NeuromodulationPMA supplementJul 17, 2025FDA
Medtronic NeuromodulationPMA supplementJul 17, 2025FDA
Medtronic NeuromodulationPMA supplementJul 28, 2025FDA
Medtronic NeuromodulationPMA supplementAug 1, 2025FDA
Medtronic NeuromodulationPMA supplementAug 6, 2025FDA
Medtronic NeuromodulationPMA supplementAug 28, 2025FDA
Medtronic NeuromodulationPMA supplementSep 5, 2025FDA
Medtronic NeuromodulationPMA supplementSep 10, 2025FDA
Medtronic NeuromodulationPMA supplementSep 15, 2025FDA
Medtronic NeuromodulationPMA supplementSep 18, 2025FDA
Medtronic NeuromodulationPMA supplementOct 16, 2025FDA
Medtronic NeuromodulationPMA supplementNov 4, 2025FDA
Medtronic NeuromodulationPMA supplementNov 26, 2025FDA
Medtronic NeuromodulationPMA supplementDec 22, 2025FDA
Medtronic NeuromodulationPMA supplementDec 23, 2025FDA
Medtronic NeuromodulationPMA supplementJan 14, 2026FDA
Medtronic NeuromodulationPMA supplementJan 20, 2026FDA
Medtronic NeuromodulationPMA supplementFeb 11, 2026FDA
Medtronic NeuromodulationPMA supplementFeb 12, 2026FDA
Medtronic NeuromodulationPMA supplementFeb 24, 2026FDA
Medtronic NeuromodulationPMA supplementFeb 27, 2026FDA
Medtronic NeuromodulationPMA supplementMar 18, 2026FDA
Medtronic NeuromodulationPMA supplementApr 3, 2026FDA
Medtronic NeuromodulationPMA supplementMay 7, 2026FDA
Medtronic NeuromodulationPMA supplementMay 22, 2026FDA
Medtronic NeuromodulationPMA supplementJun 4, 2026FDA
Medtronic NeuromodulationPMA supplementJun 5, 2026FDA
Medtronic NeuromodulationPMA supplementJun 12, 2026FDA
Medtronic NeuromodulationPMA supplementJun 16, 2026FDA
Medtronic NeuromodulationPMA supplementAug 8, 2026FDA
Medtronic NeuromodulationPMA supplementAug 14, 2026FDA
Medtronic NeuromodulationPMA supplementSep 14, 2026FDA
Medtronic NeuromodulationPMA supplementOct 6, 2026FDA
Medtronic NeuromodulationPMA supplementOct 9, 2026FDA
Medtronic NeuromodulationPMA supplementOct 29, 2026FDA

Explore the linked device profile

Other records with product code EZW

Product / regulatory recordCompanyPathwayDecision dateSource
Neuspera Medical, Inc.PMA supplementAug 21, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementAug 7, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementJul 24, 2026FDA
Axonics SNM SystemP180046/S112
BOSTON SCIENTIFIC CORPORATIONPMA supplementJun 17, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic Neuromodulation

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
7000 Central Ave., NE, Minneapolis, MN, 55432

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records